Enanta moved into the NASH race last week as well.
They've already had big success bringing in cash on their Hep C deal with AbbVie.
Now they're moving their second tier to select & advance a preclinical NASH candidate viewing the same kind of commercial opportunity as Hep C offered.
So far they are up to around $230M in cash payments & milestones received on Hep C.
Gilead in $470 million NASH deal, page-2
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.3¢ |
Change
-0.001(2.27%) |
Mkt cap ! $59.04M | |||
| Open | High | Low | Value | Volume |
| 4.4¢ | 4.4¢ | 4.2¢ | $39.11K | 895.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 752779 | 4.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.4¢ | 200000 | 1 |
View Market Depth
| Last trade - 15.58pm 04/10/2024 (20 minute delay) ? |
| SNT (ASX) Chart |